| 2025-03-18 |
详情>>
内部人交易：
PATEL SAMIR CHANDRAKANT等共交易3笔
|
| 2025-03-07 |
详情>>
股本变动：
变动后总股本504.34万股
|
| 2025-03-07 |
详情>>
业绩披露：
2024年年报每股收益-11.73美元,归母净利润-5876.9万美元,同比去年增长69.14%
|
| 2025-01-16 |
复牌提示：
2025-01-15 19:50:00 停牌，复牌日期 2025-01-16 09:00:00
|
| 2025-01-16 |
详情>>
拆分方案：
每23.0000合并分成1.0000股
|
| 2024-12-06 |
股东大会：
将于2025-01-09召开股东大会
会议内容 ▼▲
- 1.To approve an amendment to our Third Amended and Restated Certificate of Incorporation, as amended (the “Charter”), in the form attached to the accompanying proxy statement as Annex A, to, at the discretion of our Board of Directors (the “Board”), effect a reverse stock split with respect to our issued and outstanding shares of common stock, par value $0.0001 per share (“Common Stock”), including any Common Stock held by us as treasury shares, at any time prior to January 10, 2026, at a ratio of not less than 1-for-15 and not greater than 1-for-35 (the “Range”), with the ratio within the Range to be determined at the discretion of the Board without further approval or authorization of our stockholders (the “Reverse Stock Split” and such proposal is referred to as the “Reverse Stock Split Proposal”) and included in a public announcement.
2.To consider and vote upon an adjournment of the Special Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of the Reverse Stock Split Proposal.
|
| 2024-11-12 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-0.35美元,归母净利润-4050.1万美元,同比去年增长69.02%
|
| 2024-08-09 |
详情>>
业绩披露：
2024年中报每股收益-0.32美元,归母净利润-3637.5万美元,同比去年增长57.92%
|
| 2024-05-13 |
详情>>
业绩披露：
2024年一季报每股收益-0.26美元,归母净利润-3029.9万美元,同比去年增长26.43%
|
| 2024-04-23 |
股东大会：
将于2024-06-06召开股东大会
会议内容 ▼▲
- 1.To elect each of Juan Vera, M.D., Morana Jovan-Embiricos, Ph.D. and Derek Adams, Ph.D. as a Class I member of the board of directors;
2.To serve until the Company’s 2027 Annual Meeting of Stockholders and until his successor is duly elected and qualified;
3.To ratify the selection of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024;
4.To transact any other business that may properly come before the meeting or any adjournment thereof.
|
| 2024-03-15 |
详情>>
业绩披露：
2023年年报每股收益-1.83美元,归母净利润-1.9亿美元,同比去年增长-12.87%
|
| 2023-11-02 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-1.3美元,归母净利润-1.31亿美元,同比去年增长-0.11%
|
| 2023-08-03 |
详情>>
业绩披露：
2023年中报每股收益-0.92美元,归母净利润-8645万美元,同比去年增长2.32%
|
| 2023-05-04 |
详情>>
业绩披露：
2023年一季报每股收益-0.44美元,归母净利润-4118.3万美元,同比去年增长6.11%
|
| 2023-03-31 |
股东大会：
将于2023-05-11召开股东大会
会议内容 ▼▲
- 1.To elect each of Jeffrey Bornstein, Diana Brainard, M.D., David Hallal and Shawn Tomasello as a Class III member of the board of directors, to serve until the Company’s 2026 Annual Meeting of Stockholders and until his successor is duly elected and qualified;
2.To ratify the selection of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023;
3.To amend the Company’s Third Amended and Restated Certificate of Incorporation (“Charter”) to increase the authorized shares of common stock from 150,000,000 shares to 300,000,000 shares;
4.To transact any other business that may properly come before the meeting or any adjournment thereof.
|
| 2023-02-15 |
详情>>
业绩披露：
2022年年报每股收益-2.2美元,归母净利润-1.69亿美元,同比去年增长1.89%
|
| 2022-11-03 |
详情>>
业绩披露：
2022年三季报(累计)每股收益-1.83美元,归母净利润-1.31亿美元,同比去年增长-14.52%
|
| 2022-04-06 |
股东大会：
将于2022-05-17召开股东大会
会议内容 ▼▲
- 1.To elect each of Vikas Sinha and Malcolm Brenner, M.D., Ph.D. as a Class II member of the board of directors, to serve until the Company’s 2025 Annual Meeting of Stockholders and until his successor is duly elected and qualified;
2.To ratify the selection of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022;
3.To transact any other business that may properly come before the meeting or any adjournment thereof.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-04-12 |
股东大会：
将于2021-05-25召开股东大会
会议内容 ▼▲
- 1.To elect each of Juan Vera, M.D., Ansbert Gadicke, M.D., and Morana Jovan-Embiricos, Ph.D. as a Class I member of the board of directors, to serve until the Company’s 2024 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified;
2.To ratify the selection of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2021;
3.To transact any other business that may properly come before the meeting or any adjournment thereof.
|